Health‑related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study
Metadatos
Mostrar el registro completo del ítemAutor
Lozano Lorca, Macarena; Barrios Rodríguez, Rocío; Redondo Sánchez, Daniel; Cózar Olmo, José Manuel; Arrabal Martín, Miguel; García Caballos, Marta; Salcedo Bellido, Inmaculada; Sánchez Pérez, María José; Jiménez Moleón, José Juan; Olmedo Requena, María RocíoEditorial
Springer Nature
Materia
Prostate cancer Health-related quality of life Urinary symptomatology Tumour extension
Fecha
2022-11-21Referencia bibliográfica
Lozano-Lorca, M., Barrios-Rodríguez, R., Redondo-Sánchez, D. et al. Health-related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study. Qual Life Res (2022). [https://doi.org/10.1007/s11136-022-03302-z]
Patrocinador
Funding for open access charge: Universidad de Granada/CBUA; Regional Ministry of Health and Families of Andalusia/Consejería de Salud y Familias de la Junta de Andalucía (PI-0514-2016)Resumen
Purpose
To analyse the Health-Related Quality of Life (HRQoL) at diagnosis of patients with prostate cancer (PCa) according to tumour extension and urinary symptomatology and to explore factors associated with HRQoL.
Methods
408 Controls and 463 PCa cases were included. Eligibility criteria were a new diagnosis of PCa (cases), 40–80 years of age, and residence in the participating hospitals’ coverage area for ≥ 6 months before recruitment. HRQoL was evaluated using the 12-Item Short-Form Health Survey, Mental (MCS) and Physical Component Summaries (PCS), and urinary symptoms with the International Prostate Symptom Score. HRQoL scores for all PCa cases, according to tumour extension and urinary symptoms, were compared with controls. In addition, information about lifestyles and comorbidities was collected and its association with low HRQoL (lower scores) were explored using logistic regression models.
Results
Overall cases had similar PCS score, but lower MCS score than controls. The lowest standardised scores for both PCS and MCS were reached by cases with severe urinary symptoms and a metastatic tumour [mean (SD); PCS: 41.9 (11.5), MCS: 42.3 (10.3)]. Having “below” PCS and MCS scores was associated with the presence of three or more comorbidities in the cases [aOR = 2.86 (1.19–6.84) for PCS and aOR = 3.58 (1.37–9.31) for MCS] and with severe urinary symptomatology [aOR = 4.71 (1.84–12.08) for PCS and aOR = 7.63 (2.70–21.58) for MCS].
Conclusion
The mental dimension of HRQoL at diagnosis of patients with PCa was lower than in controls, especially for cases with severe urinary symptoms and a metastatic tumour. Comorbidities and urinary symptoms were variables associated with the HRQoL of PCa cases.